AKTS
Aktis Oncology, Inc. Common stock
NASDAQ: AKTS · HEALTHCARE · BIOTECHNOLOGY
$18.75
+0.16% today
Updated 2026-04-30
Market cap
$1.03B
P/E ratio
—
P/S ratio
159.27x
EPS (TTM)
$-1.21
Dividend yield
—
52W range
$15 – $29
Volume
0.4M
Aktis Oncology, Inc. Common stock (AKTS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-980044.00 | $-1.10M | $-5.55M | $-14.20M | $-17.67M | $-21.30M | $-45.20M | $-18.13M | $-30.00M | $14.76M | $-64.13M |
| Capital expenditures | $111727.00 | $47215.00 | $1.69M | $7.01M | $4.92M | $9.95M | $27.72M | $2.31M | $3.76M | $2.86M | $9.58M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $231909.00 | $435642.00 | $3.91M | $5.49M | $7.24M | $6.73M | $10.25M | $698000.00 | $1.48M | $2.26M | $5.13M |
| Free cash flow | $-1.09M | $-1.15M | $-7.23M | $-21.21M | $-22.59M | $-31.26M | $-72.92M | $-20.43M | $-33.77M | $11.90M | $-73.71M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — |